Skip to main content

Table 1 Sociodemographic, treatment and immunity characteristics of study participants

From: Cryptosporidiosis and Isosporiasis among HIV-positive individuals in south Ethiopia: a cross sectional study

Variables Cryptosporidium spp Isospora belli
  Yes No Yes No
Age (mean, ±1SD) (n = 268) 33.5, ±8.1 34.3, ±8.5 35.5, ±5.5 34.0, ±8.3
CD4 count (n = 268)     
250 67 (35.8) 120 (64.2) 3 (1.6) 184 (98.4)
251-350 14 (29.8) 33 (70.2) 1 (2.1) 46 (97.9)
351 11 (32.4) 23 (67.6) 0 (0.0) 34 (100.0)
Sex (male: female) (n = 268) 0.74:1 0.96:1 1:01 0.870;1
Treatment status (n = 268)     
On HAART 38 (28.4) 96 (71.6) 1 (0.8) 133 (99.2)
Not on HAART 54 (40.3) 80 (59.7) 3 (2.2) 131 (97.8)
HAART regimen (n = 134)     
D4T/3TC/NVP 20 (23.5) 65 (76.5) 1 (1.2) 84 (98.8)
D4T/3TC/EFV 2 (28.6) 5 (71.4) 0 (0.0) 7 (100.0)
AZT/3TC/NVP 15 (41.7) 21 (58.3) 0 (0.0) 36 (100.0)
AZT/3TC/EFV 1 (16.7) 5 (83.3) 0 (0.0) 6 (100.0)
Duration on HAART (in months) (n = 134)    
(n = 134, mean, ± 1SD) 8.9, ± 4.0 10.1 ± 5.9 9.4 ± 5.4 4.0*
2-7 months 14 (28.6) 35 (71.4)   
> = 8 months 24 (28.2) 61 (71.8)   
  1. * Among patients who have started HAART, only 1 patient was diagnosed with Isospora belli and no SD was calculated.